Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 39 for:    GDC-0973 | Recruiting, Not yet recruiting, Available Studies

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders (NACHO COBI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04079179
Recruitment Status : Not yet recruiting
First Posted : September 5, 2019
Last Update Posted : September 5, 2019
Sponsor:
Collaborators:
Texas Children's Hospital
North American Consortium for Histiocytosis
Genentech, Inc.
Information provided by (Responsible Party):
Carl Allen, Baylor College of Medicine

Brief Summary:
This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activation of a protein called Mitogen-activated protein kinase (MEK) that is part of incorrect growth signals in histiocytosis cells. Four different groups of patients will be enrolled.

Condition or disease Intervention/treatment Phase
Langerhan's Cell Histiocytosis Juvenile Xanthogranuloma Erdheim-Chester Disease Rosai Dorfman Disease Neuro-Degenerative Disease Histiocytic Sarcoma Histiocytic Disorders, Malignant Drug: Cobimetinib Phase 2

Detailed Description:

Histiocytic disorders are diseases caused by misfunctioning or buildup of particular immune cells called histiocytes. Many histiocytic disorders (LCH, juvenile xanthogranuloma (JXG), Erdheim-Chester disease (ECD), and Rosai-Dorfman Disease (RDD)) arises from blood cells that receive incorrect growth signals. These incorrect signals are caused by changes in genes (mutations) that lead to tissue damage (lesions) which causes disease. Some patients with LCH can develop neurodegeneration (LCH-ND) which is damage to neurons that results in reduced brain function, from LCH cells that go to the brain and activate inflammation. LCH arises from blood cells that receive incorrect growth signals. These incorrect signals are caused by mutations (changes in genes). The LCH blood cells can create changes in the structure of almost any organ, and can cause damage to normal organ function.

The purpose of this research study is to learn whether cobimetinib is safe and effective in subjects diagnosed with LCH, LCH-ND, RDD, JXG and ECD which may have a specfic mutation called BRAF-V600E. In healthy cells, certain proteins (called BRAF and MEK) are thought to help control normal cell growth. BRAF-V600E is a specific change in a gene that may cause cancer cells to grow and spread by sending constant signals to the MEK protein. Cobimetinib is designed to attach to and block the activity of MEK.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Participants are assigned to one of 4 groups in parallel for the duration of the study. All 4 groups receive the same intervention.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib in Refractory Langerhans Cell Histiocytosis, LCH-Associated Neurodegenerative Disease, and Other Histiocytic Disorders.
Estimated Study Start Date : August 30, 2019
Estimated Primary Completion Date : August 2024
Estimated Study Completion Date : August 2029


Arm Intervention/treatment
Experimental: Patients < 30 years with recurrent LCH (Grp1)
Children and young adults (<30 years) with recurrent active LCH lesions (may also have LCH-ND).
Drug: Cobimetinib
All groups will receive the same intervention. Cobimetinib will be given orally at a maximal dose of 60mg daily for 21 days on, then 7 days off, in a 28-day treatment cycle for a total of 12 cycles (approximately 12 months).
Other Names:
  • COTELLIC
  • RO5514041

Experimental: Patients of any age with LCH-ND (Grp2)
Patients of any age with progressive LCH Neurodegenerative Disease (LCH-ND) without other sites of active LCH.
Drug: Cobimetinib
All groups will receive the same intervention. Cobimetinib will be given orally at a maximal dose of 60mg daily for 21 days on, then 7 days off, in a 28-day treatment cycle for a total of 12 cycles (approximately 12 months).
Other Names:
  • COTELLIC
  • RO5514041

Experimental: Patients <30 years with other histiocytic disorders (Grp3)
Newly diagnosed or relapsed/refractory children and young adults (<30 years) with other histiocytic disorders including juvenile xanthogranuloma, Erdheim-Chester disease, histiocytic sarcoma and Rosai-Dorfman disease.
Drug: Cobimetinib
All groups will receive the same intervention. Cobimetinib will be given orally at a maximal dose of 60mg daily for 21 days on, then 7 days off, in a 28-day treatment cycle for a total of 12 cycles (approximately 12 months).
Other Names:
  • COTELLIC
  • RO5514041

Experimental: Patients ≥ 30 years with LCH/histiocytic disorders (Grp4)
Adults (≥30 years) with LCH or other histiocytic disorder with recurrent active lesions (may also have LCH-ND).
Drug: Cobimetinib
All groups will receive the same intervention. Cobimetinib will be given orally at a maximal dose of 60mg daily for 21 days on, then 7 days off, in a 28-day treatment cycle for a total of 12 cycles (approximately 12 months).
Other Names:
  • COTELLIC
  • RO5514041




Primary Outcome Measures :
  1. Overall Response Rates using modified RECiST criteria [ Time Frame: 12 months ]

    Proportion of participants with (complete response, partial response, stable disease, progressive disease) by 1 year of therapy with Cobimetinib.

    It is assumed that at each protocol-specified timepoint, a response assessment occurs. Status calculation will occur at each timepoint for patients who have measurable disease at baseline per the criteria defined in the protocol.



Secondary Outcome Measures :
  1. Progression Free Survival [ Time Frame: 12 months ]
    Progression Free Survival defined as the length of time during and after the treatment of a disease, that a patient lives with the disease but it does not get worse.

  2. Nature and Severity of Adverse Events [ Time Frame: 12 months ]
    Assessment of the nature and severity of adverse events in patients treated with Cobimetinib for histiocytic disorders.


Other Outcome Measures:
  1. Response assessment (Modified RECIST) of histiocytic lesions with specific mutations [ Time Frame: 12 months ]
    Response assessment using modified RECIST criteria for target lesions with specific mutations (e.g. BRAF-V600E) . Best response rate by 1 year of therapy.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA:

  • For Group 1: Participant must be less than 30 years of age at the time of enrollment
  • For Group 2: Participant may be any age at the time of enrollment
  • For Group 3: Participant must be less than 30 years of age at the time of enrollment
  • For Group 4: Participant must be 30 years of age or older at the time of enrollment
  • Participant must be able to take an enteral dose and formulation of medication. Study medication is only available as an oral suspension or tablet which may be taken by mouth or other enteral route such as nasogastric or gastric tube.
  • Biopsy proven LCH -AND
  • Failure of at least front-line therapy for high-risk LCH with evaluable disease. -OR
  • Failure of at least second-line therapy for low-risk LCH with evaluable disease. -OR
  • Diagnosis of LCH-associated neurodegenerative disease with radiologic or clinical progression within the past 3 months. -OR
  • Biopsy proven JXG, ECD, RDD, histiocytic sarcoma, or other histiocytic lesion (newly diagnosed or relapsed/refractory disease) with evaluable active disease.

Performance Level:

-Karnofsky ≥ 50% for patients > 16 years of age and Lansky ≥ 50% for patients ≤ 16 years of age.

Adequate Hematologic Function Defined as:

  • ANC ≥ 0.75 x 10^9/L (unsupported/without growth factor stimulant)
  • Platelet count ≥ 75 x 10^9/L (unsupported/without transfusion within the past 7 days).
  • Patients with marrow disease must have platelet count of >/= 75 x 10^9/L (transfusion support allowed) and must not be refractory to platelet transfusions.
  • Hemoglobin ≥ 8 g/dL (unsupported/without transfusion within the past 7 days)
  • Patients with marrow disease must have hemoglobin ≥ 8 g/dL (transfusion support allowed).

Adequate Renal Function Defined as:

- Calculated creatinine clearance (or radioisotope GFR) ≥ 70 mL/min/1.73m^2 or serum creatinine based on age/gender as follows:

Maximum Serum Creatinine (mg/dL) Age 2 to < 6 years: Male 0.8 mg/d, Female 0.8; 6 to < 10 years: Male 1 mg/dL,Female 1; 10 to < 13 years: Male 1.2 mg/dL; Female 1.2; 13 to < 16 years: Male 1.5 mg/dL ; Female 1.4;

≥ 16 years: Male 1.7 mg/dL; Female 1.4;

Adequate Liver Function Defined as:

  • Bilirubin (sum of conjugated + unconjugated) ≤ 1.5 x upper limit of normal (ULN) for age
  • AST and ALT ≤ 2.5x ULN for age.
  • Serum albumin ≤ 2 g/dL.

For patients with liver disease caused by histiocytic disorder:

• Patients may be enrolled with abnormal bilirubin, AST, ALT and albumin with documentation of histiocytic liver disease.

Adequate Cardiac Function Defined as:

  • Fractional shortening (FS) of ≥ 30% or ejection fraction of ≥ 50% by echocardiogram at baseline, as determined by echocardiography or multigated acquisition scan (MUGA) within 21 days prior to study enrollment. Depending on institutional standard, either FS or LVEF is adequate for enrollment if only one value is measured; if both values are measured, then both values must meet criteria above
  • Female patients of childbearing potential require a negative urine or serum pregnancy test for eligibility and again at enrollment, if more than 2 weeks has elapsed.
  • Female patients of childbearing potential must agree to follow the contraceptive requirements using two forms of effective contraceptive methods for the duration of the study treatment.

EXCLUSION CRITERIA:

- Prior and Concomitant Use of Drugs with CYP3A4 inducing/inhibiting activity: Patient taking strong inducers or inhibitors of CYP3A4 within 14 days prior to study enrollment, including but not limited to the following: erythromycin, clarithromycin, ketoconazole, azithromycin, itraconazole, grapefruit juice or St. John's wort.

  • Prior Therapy Restrictions Completion of previous chemotherapy, immunotherapy, radiotherapy, or targeted therapy for LCH (or other histiocytic disorder) at least 28 days (except where specified below) prior to study enrollment, with resolution of all associated toxicity to ≤ Grade 1 prior to study enrollment (exception for alopecia and ototoxicity which do not need to be resolved ≤ Grade 1). Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment. If after the required timeframe, the laboratory eligibility criteria are met, the patient is considered to have recovered adequately.

    • Radiation therapy within the last 28 days.
    • Any prior treatment with Cobimetinib.
    • Treatment with a long-acting hematopoietic growth factor within 14 days prior to initiation of study drug or a short-acting hematopoietic growth factor within 7 days prior to study enrollment.
    • Treatment with hormonal therapy (except hormone replacement therapy or oral contraceptives), immunotherapy, biologic therapy, investigational therapy, or herbal cancer therapy within 28 days or < 5 half-lives, whichever is longer, prior to study enrollment.
    • Treatment with high-dose chemotherapy and stem-cell rescue (autologous stem cell transplant) or allogeneic stem cell transplant within 90 days prior to study enrollment. Anti-GVHD agents post-transplant: Patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial.
    • For patients with brain tumors (intracranial masses), use of anticoagulants within 7 days prior to study enrollment.
    • Corticosteroid therapy <0.5 mg/kg/day averaged during the month prior to study enrollment is permissible but must be discontinued fourteen (14) days prior to prior to study enrollment. Patients with documented brain lesions receiving corticosteroids for management of cerebral edema must be on a stable dose for fourteen (14) days prior to study enrollment.
    • Patient has received treatment with investigational therapy within 4 weeks prior to initiation of study drug.
  • Exclusions for other illness

    • Other active malignancy or history of secondary malignancy.
    • Refractory nausea and vomiting, malabsorption, external biliary shunt
    • Infection: Patients who have a known active infection (excluding documented fungal infection of the nail beds) within 28 days prior to study enrollment that has not completely resolved.
    • Major surgical procedure or significant traumatic injury within 28 days prior to study enrollment, or anticipation of need for major surgical procedure during the course of the study. Placement of a vascular access device or minor surgery is permitted within fourteen (14) days of study enrollment (provided that the wound has healed).
    • History of significant bowel resection that would preclude adequate absorption or other significant malabsorptive disease.
    • History of pneumonitis.
    • Ophthalmologic considerations: Patients with known significant ophthalmologic conditions or known risk factors for retinal vein occlusion are not eligible. Specifically, patients with a history of retinal vein occlusion (RVO), retinal detachment, retinal pathology on ophthalmologic exam, retinopathy of prematurity, central serous chorioretinopathy (CSSCR), neovascular retinopathy, intraocular pressure > 21 mmHg, and predisposing factors to RVO (e.g., uncontrolled hypertension, diabetes, or hyperlipidemia, coagulopathy) will be excluded. Patients with longstanding and stable ophthalmologic findings secondary to existing conditions are eligible with appropriate documentation and approval from Study (Co)Chair and Coordinating Center.
    • History of solid organ transplantation: Patients who have received a prior solid organ transplantation are not eligible.
    • Any other disease, metabolic or psychological dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that in the opinion of the investigator contraindicates use of an investigational drug or places the patient at unacceptable risk from treatment complications.
  • History of clinically significant cardiac dysfunction, including the following:

    • Clinically significant cardiac arrhythmias including brady-arrhythmias and/or patients who require anti-arrhythmic therapy (with the exception of beta blockers or digoxin). Patients with controlled atrial fibrillation are not excluded.
    • Unstable arrhythmia
    • Unstable angina, or new-onset angina within 3 months prior to initiation of study treatment
    • Symptomatic congestive heart failure, defined as New York Heart Association Class II or higher
    • Myocardial infarction within 3 months prior to initiation of study treatment
  • Known chronic human immunodeficiency virus (HIV).
  • History of Grade ≥ 2 CNS hemorrhage or history of any CNS hemorrhage within 28 days of study entry.
  • Female patients who are pregnant or lactating. Pregnant or lactating women will not be entered on this study because there is no available information regarding human fetal or teratogenic toxicities.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04079179


Contacts
Layout table for location contacts
Contact: Carl E Allen, MD, PhD 832-822-4242 ceallen@texaschildrens.org
Contact: Olive Eckstein, MD 832-822-4242 Eckstein@bcm.edu

Locations
Layout table for location information
United States, Tennessee
NACHO Consortium Not yet recruiting
Memphis, Tennessee, United States, 38105
Contact: Sara Clyburn    901-595-6042    Sara.Clyburn@STJUDE.ORG   
Contact: Heidi Clough    901-595-0362    Heidi.Clough@STJUDE.ORG   
United States, Texas
Texas Children's Hospital
Houston, Texas, United States, 77030
Sponsors and Collaborators
Carl Allen
Texas Children's Hospital
North American Consortium for Histiocytosis
Genentech, Inc.
Investigators
Layout table for investigator information
Study Chair: Carl E Allen, MD, PhD Baylor College of Medicine

Layout table for additonal information
Responsible Party: Carl Allen, Associate Professor, Baylor College of Medicine
ClinicalTrials.gov Identifier: NCT04079179     History of Changes
Other Study ID Numbers: H-43475 NACHO COBI
First Posted: September 5, 2019    Key Record Dates
Last Update Posted: September 5, 2019
Last Verified: September 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Carl Allen, Baylor College of Medicine:
Cobimetinib
Langerhans Cell Histiocytosis (LCH)
Additional relevant MeSH terms:
Layout table for MeSH terms
Histiocytic Sarcoma
Histiocytic Disorders, Malignant
Histiocytosis, Langerhans-Cell
Neurodegenerative Diseases
Histiocytosis
Erdheim-Chester Disease
Xanthogranuloma, Juvenile
Histiocytosis, Sinus
Neoplasms by Histologic Type
Neoplasms
Lymphatic Diseases
Lung Diseases, Interstitial
Lung Diseases
Respiratory Tract Diseases
Histiocytosis, Non-Langerhans-Cell
Nervous System Diseases
Skin Diseases